| Acute GvHD II–IV | Chronic GvHD | Relapse | NRM | LFS | OS | GRFS | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | HR (95%CI) | p | HR (95% CI) | p | |
Donor type | ||||||||||||||
 SUCBT vs. Haplo | 1.03 (0.56–1.89) | 0.923 | 1.86 (0.70–4.95) | 0.21 | 0.81 (0.32–2.04) | 0.65 | 2.63 (1.44–4.83) | 0.002 | 1.95 (1.20–3.16) | 0.007 | 2.19 (1.31–3.65) | 0.003 | 2.39 (1.51–3.79) | < 0.001 |
 Year of HSCT | 0.97 (0.85–1.11) | 0.677 | 0.91 (0.77–1.08) | 0.30 | 0.93 (0.76–1.14) | 0.50 | 1.01 (0.88–1.15) | 0.925 | 0.98 (0.88–1.10) | 0.772 | 1.00 (0.89–1.12) | 1.000 | 1.07 (0.97–1.189) | 0.197 |
 Age (per 10 years) | 0.89 (0.72–1.08) | 0.236 | 1.17 (0.93–1.47) | 0.19 | 1.07 (0.80–1.42) | 0.66 | 1.20 (0.99–1.47) | 0.071 | 1.15 (0.98–1.35) | 0.096 | 1.18 (0.99–1.40) | 0.055 | 1.11 (0.96–1.29) | 0.164 |
Karnofsky PS | ||||||||||||||
 ≥ 90 vs. < 90 | 0.67 (0.35–1.31) | 0.243 | 1.05 (0.44–2.55) | 0.91 | 0.35 (0.15–0.81) | 0.01 | 0.60 (0.33–1.09) | 0.094 | 0.50 (0.31–0.81) | 0.005 | 0.60 (0.36–1.00) | 0.053 | 0.58 (0.36–0.92) | 0.020 |
Disease status at HSCT | ||||||||||||||
 CR2 vs. CR1 | 1.16 (0.68–1.98) | 0.582 | 0.89 (0.44–1.79) | 0.74 | 0.79 (0.34–1.84) | 0.59 | 1.19 (0.70–1.20) | 0.524 | 1.07 (0.69–1.66) | 0.760 | 1.19 (0.76–1.87) | 0.457 | 0.92 (0.61–1.39) | 0.703 |
Female donor to male recipient | ||||||||||||||
 Yes vs. No | 1.63 (0.97–2.73) | 0.064 | 1.15 (0.60–2.18) | 0.67 | 1.25 (0.57–2.73) | 0.58 | 1.84 (1.12–3.02) | 0.016 | 1.67 (1.11–2.53) | 0.014 | 1.67 (1.08–2.58) | 0.020 | 1.55 (1.05–2.28) | 0.027 |
 Center |  | 0.935 |  | < 0.001 |  | 0.94 |  | 0.262 |  | 0.924 |  | 0.278 |  | 0.206 |